Trial Profile
Phase I trial of MGC-018
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 14 May 2018
Price :
$35
*
At a glance
- Drugs Vobramitamab duocarmazine (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 14 May 2018 New trial record
- 07 May 2018 According to a Macrogenics media release, the company expects to initiate this trial in the second half of 2018.